Thyroid Eye Disease

Veligrotug Delivers Rapid, Durable Benefit in Active Thyroid Eye Disease in the Phase 3 THRIVE Trial

By MedXY 06/06/2026

In phase 3 testing, veligrotug produced rapid and clinically meaningful reductions in proptosis, diplopia, and disease activity in active thyroid eye disease, with durable benefit through 52 weeks and a favorable short-term safety profile.

Diabetes & Endocrinology news Ophthalmology

Tocilizumab Shows Promising Benefits in Glucocorticoid-Resistant Thyroid Eye Disease

By MedXY 05/13/2026

In two prospective cohorts of active, glucocorticoid-resistant thyroid eye disease, tocilizumab improved eye inflammation, proptosis, diplopia, and quality of life with acceptable safety, supporting IL-6 blockade as a promising second-line treatment.

Diabetes & Endocrinology news Ophthalmology

Teprotumumab for Thyroid Eye Disease Carries a Measurable Long-Term Dysglycemia Risk

By MedXY 05/03/2026

A large multinational cohort study found that teprotumumab use in thyroid eye disease was associated with higher risks of prediabetes, diabetes, and antidiabetes medication initiation over 5 years.

Diabetes & Endocrinology Ophthalmology Specialties

IBI311, an IGF-1R Inhibitor, Shows Promising Results for Active Thyroid Eye Disease in Chinese Patients: Insights from the RESTORE-1 Trial

By MedXY 10/15/2025

The RESTORE-1 phase 3 trial demonstrates that IBI311 significantly improves proptosis and inflammation in Chinese patients with active thyroid eye disease, with a favorable safety profile.

Clinical Updates Diabetes & Endocrinology news Ophthalmology Specialties

Veligrotug Emerges as a Promising Therapy for Thyroid Eye Disease: Insights from the THRIVE and THRIVE-2 Trials

By MedXY 07/31/2025

Veligrotug demonstrates robust efficacy and manageable safety in both active and chronic thyroid eye disease, positioning itself as a potential alternative to teprotumumab based on phase 3 THRIVE trial data.